Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Dow
Express Scripts
McKinsey
Colorcon

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Defactinib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Defactinib: Patents, clinical trial progress, indications

Defactinib is an investigational drug.

There have been 13 clinical trials for Defactinib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and NHS Greater Glasgow and Clyde.

There are four US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for Defactinib
TitleSponsorPhase
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaMerck Sharp & Dohme Corp.Phase 2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaVerastem, Inc.Phase 2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2

See all Defactinib clinical trials

Clinical Trial Summary for Defactinib

Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib

See all Defactinib clinical trials

US Patents for Defactinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Defactinib   See Pricing Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer Inc (New York, NY)   See Pricing
Defactinib   See Pricing Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer Inc (New York, NY)   See Pricing
Defactinib   See Pricing Sulfonyl amide derivatives for the treatment of abnormal cell growth   See Pricing
Defactinib   See Pricing Methods and compositions for treating abnormal cell growth Verastem, Inc. (Needham, MA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Defactinib

Drugname Country Document Number Estimated Expiration Related US Patent
Defactinib Argentina 066125 2027-04-18   See Pricing
Defactinib Australia 2008240359 2027-04-18   See Pricing
Defactinib Brazil PI0810411 2027-04-18   See Pricing
Defactinib Canada 2684447 2027-04-18   See Pricing
Defactinib Chile 2008001076 2027-04-18   See Pricing
Defactinib China 101678215 2027-04-18   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
AstraZeneca
Harvard Business School
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.